5-05-2025, 18:49

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

Notified -
Globe Newswire5-05-2025, 18:49
21-02-2025, 18:00

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Notified -
Globe Newswire21-02-2025, 18:00
27-01-2025, 18:00

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Notified -
Globe Newswire27-01-2025, 18:00
28-02-2023, 07:27

Alvotech Announces Webcast of 2022 Full Year Financial

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar
Globe Newswire28-02-2023, 07:27
6-02-2023, 16:08

Alvotech enters into commercialization agreement with

Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area,
Globe Newswire6-02-2023, 16:08